Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TK1 | P04183 | 2/20 | 0.64 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.64 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.64 |
| ▸ | TSHR | P16473 | 1/20 | 0.64 |
| ▸ | BLM | P54132 | 1/20 | 0.64 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.64 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.64 |
| ▸ | DNMT1 | P26358 | 8/20 | 0.57 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.57 |
| ▸ | DNMT3B | Q9UBC3 | 3/20 | 0.50 |
| ▸ | LMNA | P02545 | 2/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.45 |
| ▸ | PNP | P00491 | 1/20 | 0.45 |
| ▸ | TP53 | P04637 | 1/20 | 0.45 |
| ▸ | HTT | P42858 | 1/20 | 0.45 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.45 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.45 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.45 |
| ▸ | FPR2 | P25090 | 2/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL447251 | 1.00 | TK1 (0.64) | TK1CYP1A2CYP3A4TSHRBLM | |
| SCHEMBL447249 | 1.00 | TK1 (0.64) | TK1CYP1A2CYP3A4TSHRBLM | |
| SCHEMBL5982338 | 1.00 | TK1 (0.64) | TK1CYP1A2CYP3A4TSHRBLM | |
| SCHEMBL6359874 | 1.00 | TK1 (0.64) | TK1CYP1A2CYP3A4TSHRBLM | |
| SCHEMBL9803687 | 0.91 | DNMT1 (0.57) | TK1CYP1A2CYP3A4TSHRBLM | |
| SCHEMBL9803679 | 0.91 | DNMT1 (0.57) | TK1CYP1A2CYP3A4TSHRBLM | |
| SCHEMBL5982360 | 0.91 | DNMT1 (0.57) | TK1CYP1A2CYP3A4TSHRBLM | |
| SCHEMBL9803693 | 0.91 | DNMT1 (0.57) | TK1CYP1A2CYP3A4TSHRBLM | |
| SCHEMBL2293952 | 0.89 | DNMT1 (0.57) | TK1CYP1A2CYP3A4TSHRBLM | |
| SCHEMBL5982097 | 0.89 | DNMT1 (0.57) | TK1CYP1A2CYP3A4TSHRBLM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120219602-A1 | METHODS FOR TREATING HERPES VIRUS INFECTIONS | NANOBIO CORPORATION | 2012-08-30 | — | — | US | claimed |
| EP-2280690-A2 | METHODS FOR TREATING HERPES VIRUS INFECTIONS | Nanobio Corporation (US) | 2011-02-09 | — | — | EP | claimed |
| US-20100075914-A1 | METHODS FOR TREATING HERPES VIRUS INFECTIONS | NANOBIO CORPORATION | 2010-03-25 | — | — | US | claimed |
| WO-2009129470-A2 | METHODS FOR TREATING HERPES VIRUS INFECTIONS | NANOBIO CORPORATION (US) | 2009-10-22 | — | — | WO | claimed |
| US-4382925-A | VIRICIDES, ESPECIALLY AGAINST HERPES VIRUS | THE UNIVERSITY OF BIRMINGHAM (GB) | 1983-05-10 | — | — | US | claimed |
| WO-2013130535-A1 | TOPICAL DELIVERY OF HORMONAL AND NON HORMONAL NANO FORMULATIONS, METHODS OF MAKING AND USING THE SAME | NEWGEN BIOPHARMA CORPORATION (US) | 2013-09-06 | — | — | WO | disclosed |
| US-20130224268-A1 | TOPICAL DELIVERY OF HORMONAL AND NON HORMONAL NANO FORMULATIONS, METHODS OF MAKING AND USING THE SAME | NEWGEN BIOPHARMA CORP. (US) | 2013-08-29 | — | — | US | disclosed |
| US-20120219602-A1 | METHODS FOR TREATING HERPES VIRUS INFECTIONS | NANOBIO CORPORATION | 2012-08-30 | — | — | US | disclosed |
| US-20120064136-A1 | ANTI-AGING AND WRINKLE TREATMENT METHODS USING NANOEMULSION COMPOSITIONS | NANOBIO CORPORATION | 2012-03-15 | — | — | US | disclosed |
| EP-2280690-A2 | METHODS FOR TREATING HERPES VIRUS INFECTIONS | Nanobio Corporation (US) | 2011-02-09 | — | — | EP | disclosed |
| US-20100075914-A1 | METHODS FOR TREATING HERPES VIRUS INFECTIONS | NANOBIO CORPORATION | 2010-03-25 | — | — | US | disclosed |
| WO-2009129470-A2 | METHODS FOR TREATING HERPES VIRUS INFECTIONS | NANOBIO CORPORATION (US) | 2009-10-22 | — | — | WO | disclosed |
| US-4990499-A | Treatment of infections and neoplasms | UNIVERSITY OF SASKATCHEWAN (CA) | 1991-02-05 | — | — | US | disclosed |
| EP-0339161-A1 | Novel fluorophosphonate nucleotide derivatives | MERRELL DOW PHARMACEUTICALS INC. (US) | 1989-11-02 | — | — | EP | disclosed |
| EP-0335770-A2 | Novel fluorophosphonate nucleotide derivatives | MERRELL PHARMACEUTICALS INC. (US) | 1989-10-04 | — | — | EP | disclosed |
| US-4382925-A | VIRICIDES, ESPECIALLY AGAINST HERPES VIRUS | THE UNIVERSITY OF BIRMINGHAM (GB) | 1983-05-10 | — | — | US | disclosed |
| US-4382925-A | VIRICIDES, ESPECIALLY AGAINST HERPES VIRUS | THE UNIVERSITY OF BIRMINGHAM (GB) | 1983-05-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100075914-A1 | METHODS FOR TREATING HERPES VIRUS INFECTIONS | STING1, IFNG, NGF | TK1 18/4885CYP1A2 4640/4885CYP3A4 4587/4885 |
| US-20130224268-A1 | TOPICAL DELIVERY OF HORMONAL AND NON HORMONAL NANO FORMULATIONS, METHODS OF MAKING AND USING THE SAME | SHBG, NR5A1, CYP19A1 | TK1 3205/4885CYP1A2 666/4885CYP3A4 1522/4885 |
| US-20120219602-A1 | METHODS FOR TREATING HERPES VIRUS INFECTIONS | STING1, IFNG, NGF | TK1 18/4885CYP1A2 4640/4885CYP3A4 4587/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.